Milestone Pharmaceuticals Valuation
| MIST Stock | USD 1.85 0.01 0.54% |
Based on Macroaxis valuation methodology, the firm appears to be undervalued. Milestone Pharmaceuticals secures a last-minute Real Value of $4.7 per share. The latest price of the firm is $1.85. Our model forecasts the value of Milestone Pharmaceuticals from analyzing the firm fundamentals such as Return On Equity of -1.34, current valuation of 76.79 M, and Shares Owned By Insiders of 0.69 % as well as examining its technical indicators and probability of bankruptcy. Key fundamental drivers impacting Milestone Pharmaceuticals' valuation include:
Price Book 4.1308 | Enterprise Value 76.8 M | Enterprise Value Ebitda (1.43) | Price Sales 91.9492 | Enterprise Value Revenue 81.4416 |
Undervalued
Today
Please note that Milestone Pharmaceuticals' price fluctuation is slightly risky at this time. Calculation of the real value of Milestone Pharmaceuticals is based on 3 months time horizon. Increasing Milestone Pharmaceuticals' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Milestone Pharmaceuticals' intrinsic value may or may not be the same as its current market price of 1.85, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 1.85 | Real 4.7 | Target 13.0 | Hype 1.85 | Naive 1.71 |
The intrinsic value of Milestone Pharmaceuticals' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Milestone Pharmaceuticals' stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Milestone Pharmaceuticals helps investors to forecast how Milestone stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Milestone Pharmaceuticals more accurately as focusing exclusively on Milestone Pharmaceuticals' fundamentals will not take into account other important factors: Traditionally, analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. For example, some money managers use Milestone Pharmaceuticals' intrinsic value based on its ongoing forecasts of Milestone Pharmaceuticals' financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by looking to relative value analysis against Milestone Pharmaceuticals' closest peers.
Milestone Pharmaceuticals Cash |
|
Milestone Valuation Trend
Milestone Pharmaceuticals' real value is important for investors to make better decisions and a more accurate overall view of Milestone Pharmaceuticals' financial worth over time. Using both Milestone Pharmaceuticals' enterprise value as well as its market capitalization is the best way to gauge the value of the company and is usually enough for investors to make market timing conclusions.
Milestone Pharmaceuticals Total Value Analysis
Milestone Pharmaceuticals is now projected to have valuation of 76.79 M with market capitalization of 99.19 M, debt of 51.77 M, and cash on hands of 86.24 M. Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the Milestone Pharmaceuticals fundamentals before making equity appraisal based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
76.79 M | 99.19 M | 51.77 M | 86.24 M |
Milestone Pharmaceuticals Investor Information
About 57.0% of the company shares are owned by institutional investors. The book value of Milestone Pharmaceuticals was now reported as 0.39. The company recorded a loss per share of 0.8. Milestone Pharmaceuticals had not issued any dividends in recent years. The entity had 1-1 split on the 24th of March 2020. Based on the key indicators related to Milestone Pharmaceuticals' liquidity, profitability, solvency, and operating efficiency, Milestone Pharmaceuticals is not in a good financial situation at this time. It has a very high probability of going through financial hardship in December.Milestone Pharmaceuticals Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Milestone Pharmaceuticals has an asset utilization ratio of 1.33 percent. This implies that the Company is making $0.0133 for each dollar of assets. An increasing asset utilization means that Milestone Pharmaceuticals is more efficient with each dollar of assets it utilizes for everyday operations.Milestone Pharmaceuticals Ownership Allocation
Milestone Pharmaceuticals maintains a total of 53.33 Million outstanding shares. Over half of Milestone Pharmaceuticals' outstanding shares are owned by institutional investors. These institutional investors are typically referred to as corporate investors that shop for positions in a given instrument to benefit from reduced trade commissions. Please note that no matter how many assets the company has, if the real value of the firm is less than the current market value, you may not be able to make money on it.Milestone Pharmaceuticals Profitability Analysis
The company reported the previous year's revenue of 1000 K. Net Loss for the year was (59.69 M) with profit before overhead, payroll, taxes, and interest of 5 M.About Milestone Pharmaceuticals Valuation
The stock valuation mechanism determines Milestone Pharmaceuticals' current worth on a daily basis. In general, an absolute valuation approach attempts to find the value of Milestone Pharmaceuticals based exclusively on its fundamental and basic technical indicators. As compared to an absolute model, our relative valuation model uses a comparative analysis of Milestone Pharmaceuticals. We calculate exposure to Milestone Pharmaceuticals's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Milestone Pharmaceuticals's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | 402 K | 381.9 K | |
| Pretax Profit Margin | (59.68) | (56.70) | |
| Operating Profit Margin | (61.10) | (58.04) | |
| Net Loss | (59.68) | (56.70) | |
| Gross Profit Margin | 0.40 | 0.72 |
Milestone Pharmaceuticals Growth Indicators
Investing in growth stocks can be very risky. If the company such as Milestone Pharmaceuticals does not do well, investors take a loss on the stock when it is time to sell. Also, because growth stocks typically do not pay dividends, the only opportunity an investor has to make money on their investment is when they eventually sell their shares.
| Common Stock Shares Outstanding | 43 M |
Milestone Pharmaceuticals Current Valuation Indicators
Milestone Pharmaceuticals' valuation analysis is a process of estimating the intrinsic value of all assets and outstanding equities. There are different methodologies and models we use to develop the final Milestone Pharmaceuticals' valuation. The techniques such as discounted cash flow and fundamental indicators such as book value per share or market capitalization are well known and widely used across most financial advisers and money managers.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as Milestone Pharmaceuticals, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use Milestone Pharmaceuticals' valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes Milestone Pharmaceuticals' worth.Additional Tools for Milestone Stock Analysis
When running Milestone Pharmaceuticals' price analysis, check to measure Milestone Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Milestone Pharmaceuticals is operating at the current time. Most of Milestone Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Milestone Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Milestone Pharmaceuticals' price. Additionally, you may evaluate how the addition of Milestone Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.